46 completed, 8 terminated, 5 unknown, 2 withdrawn. 62 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 62 | Completed 46, Terminated 8, Unknown 5, Withdrawn 2, Recruiting 1 |
| Phase 2 | 7 | Completed 5, Recruiting 1, Unknown 1 |
Follow Mesalamine: new trials by email Literature Review of Mesalamine trials Research Report on Mesalamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis Mesalamine, Placebo - Ulcerative Colitis (UC) | Phase 3 | Withdrawn | AbbVie | 2025-09-15 | 2025-08-12 | |
| Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis. Mesalazine - Colitis, Ulcerative | Phase 3 | Unknown | Faes Farma, S.A. | 376 | 2024-03-01 | 2023-12-19 |
| Dapagliflozin in Patients With Ulcerative Colitis Mesalamine, Dapagliflozin 10mg Tab - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Mostafa Bahaa | 60 | 2023-08-20 | 2026-09-21 |
| Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis Mesalamine, Nifuroxazide - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Mostafa Bahaa | 50 | 2023-08-20 | 2026-10-13 |
| Fenofibrate in Ulcerative Colitis Mesalamine, Fenofibrate 160mg - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Tanta University | 60 | 2023-02-28 | 2026-05-04 |
| Fecal Microbiota Transplantation for Ulcerative Colitis Fecal microbiota transplantation, Infusion of Saline, 5-Aminosalicylic acid(5-ASA) and/or Prednisone - Ulcerative Colitis, Fecal Microbiota Transplantation | Phase 2 / Phase 3 | Recruiting | Guangzhou First People's Hospital | 120 | 2019-01-20 | 2019-01-15 |
| Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC Fecal Microbiota Transplantation, Mesalamine Granules, Placebo infusion - Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate | Phase 3 | Unknown | Dayanand Medical College and Hospital | 20 | 2018-12-01 | 2019-02-12 |
| To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis Budesonide (6 mg), Budesonide (9 mg), Mesalazine (3,600 mg) - Colitis, Ulcerative | Phase 3 | Completed | Ferring Pharmaceuticals | 274 | 2018-03-02 | 2020-06-18 |
| Mercaptopurine Therapy in Ulcerative Colitis Mercaptopurine (Purinethol), Placebo, Mesalamine - Colitis, Ulcerative | Phase 3 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 136 | 2016-11-01 | 2020-01-07 |
| Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis). 5-ASA, Corticosteroids - Ulcerative Colitis | Phase 3 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 160 | 2016-06-13 | 2021-08-26 |
| The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer Mesalazine Sustained-Release Tablets, Riboflavin Sodium Phosphate Injection - Crohn's Disease, Oral Ulcer | Phase 3 | Withdrawn | Xijing Hospital of Digestive Diseases | 2016-03-01 | 2023-02-01 | |
| Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis Bio-enhanced Curcumin Soft Gelatin Capsule, 5-Aminosalicylic acid - Ulcerative Colitis | Phase 3 | Unknown | Asian Institute of Gastroenterology, India | 50 | 2016-02-01 | 2016-02-23 |
| Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC) Mesalamine, Placebo - Ulcerative Colitis | Phase 3 | Completed | Ferring Pharmaceuticals | 276 | 2016-02-01 | 2021-11-08 |
| Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC) Mesalamine, Placebo - Ulcerative Colitis | Phase 3 | Completed | Ferring Pharmaceuticals | 228 | 2015-10-01 | 2021-03-15 |
| Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose) - Ulcerative Colitis | Phase 3 | Completed | Shire | 107 | 2014-12-12 | 2021-06-09 |
| Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) LT-02, Placebo, Mesalamine - Ulcerative Colitis | Phase 3 | Completed | Dr. Falk Pharma GmbH | 150 | 2014-10-01 | 2020-01-27 |
| Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission Mesalazine, Tripterygium glycosides - Inflammatory Bowel Diseases, Crohn's Disease | Phase 2 / Phase 3 | Unknown | Zhu Weiming | 40 | 2014-01-01 | 2014-01-24 |
| TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC) TP05, Asacol 400 mg - Acute Ulcerative Colitis | Phase 3 | Completed | Tillotts Pharma AG | 817 | 2013-07-01 | 2018-08-08 |
| Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan D9421-C capsule 3 mg, Mesalazine tablets - Crohn's Disease | Phase 3 | Completed | AstraZeneca | 123 | 2012-02-01 | 2016-10-31 |
| Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis Curcumin, 5-aminosalicylic acid - Ulcerative Colitis | Phase 3 | Completed | Sheba Medical Center | 50 | 2011-07-01 | 2016-02-12 |
Showing 20 of 62. Sign in to see all of them.
Colitis, Ulcerative (35) · Crohn Disease (8) · Inflammatory Bowel Diseases (6) · Colitis (4) · Diverticulitis (4) · Irritable Bowel Syndrome (3) · Ulcer (3) · Abdominal Pain (2) · Diarrhea (2) · Gastrointestinal Diseases (2) · Proctitis (2) · Recurrence (2) · Acute Disease (1) · Colitis, Collagenous (1) · Colitis, Lymphocytic (1)
Dr. Falk Pharma GmbH (10) · Ferring Pharmaceuticals (8) · Shire (6) · Warner Chilcott (5) · Tillotts Pharma AG (4) · SOFAR S.p.A. (3) · Bausch Health Americas, Inc. (2) · Mostafa Bahaa (2) · AbbVie (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Asian Institute of Gastroenterology, India (1) · AstraZeneca (1) · Cardiff and Vale University Health Board (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Dayanand Medical College and Hospital (1)
United States (21) · Germany (13) · Canada (12) · Poland (8) · India (7) · France (6) · Hungary (6) · United Kingdom (6) · Belgium (5) · China (5) · Italy (5) · Netherlands (5) · Romania (5) · Russia (5) · Sweden (5)
Wolfgang Kruis, Professor (3) · Piotr Krzeski, MD (2) · Stephan Miehlke, Professor (2) · Ajit Sood, DM (1) · Alon Lang, MD (1) · Andreas Tromm, Professor (1) · Ashok Tuteja (1) · Axel Dignass, Prof Dr (1) · Barbara Giovanni, Doctor (1) · Brian Feagan, MD (1)
PMID 21255059, PMID 21385195, PMID 25038431, PMID 28543263, PMID 28707787, PMID 28707796, PMID 40013523, PMID 17241860, PMID 18272546, PMID 18671232, PMID 18832520, PMID 20551460, PMID 21070781, PMID 21138455, PMID 21453882, PMID 22892337, PMID 23451806, PMID 23528626, PMID 23754545, PMID 24440672, PMID 25419597, PMID 25533646, PMID 25724700, PMID 26898569, PMID 26905266, PMID 28274254, PMID 28568974, PMID 30195447, PMID 31546056, PMID 32889959, PMID 33279779, PMID 37806372, PMID 37855022, PMID 40620467, PMID 41330887
2004 (5), 2015 (3), 2009 (2), 2008 (1)